Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Critical role for Daxx in regulating Mdm2.

Jun Tang1, Li-Ke Qu, Jianke Zhang

  • 1Abramson Family Cancer Research Institute and Department of Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Nature Cell Biology
|July 18, 2006
PubMed
Summary

Death domain-associated protein (Daxx) stabilizes mouse double minute 2 (Mdm2), a key regulator of the tumor suppressor p53. Disrupting the Mdm2-Daxx interaction is crucial for p53 activation following DNA damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics.

Journal for immunotherapy of cancer·2026
Same author

CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity.

Journal for immunotherapy of cancer·2025
Same author

Intratumoral injection and retention hold promise to improve cytokine therapies for cancer.

Frontiers in oncology·2024
Same author

CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity.

Cancer immunology research·2024
Same author

CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease.

The Journal of experimental medicine·2024
Same author

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.

Journal for immunotherapy of cancer·2023

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • The tumor suppressor p53 regulates apoptosis and cell-cycle arrest in response to cellular stress.
  • Mouse double minute 2 (Mdm2) restrains p53's anti-proliferative functions by promoting its ubiquitination and degradation.
  • The differential regulation of Mdm2's opposing E3 ligase activities (cis- and trans-) remains unclear.

Purpose of the Study:

  • To investigate the role of death domain-associated protein (Daxx) in regulating Mdm2 stability and function.
  • To elucidate the mechanism by which Daxx influences Mdm2's interaction with p53 and its auto-ubiquitination.
  • To understand how the Mdm2-Daxx interaction is modulated during cellular stress, particularly DNA damage.

Main Methods:

  • Investigated the effect of Daxx downregulation and overexpression on Mdm2 protein levels.

Related Experiment Videos

  • Assessed the interaction between Daxx, Mdm2, and the deubiquitinase Hausp using co-immunoprecipitation assays.
  • Examined the impact of Daxx on Mdm2's E3 ligase activity towards p53.
  • Analyzed the dissociation of Daxx from Mdm2 upon DNA damage induction.

    • Main Results:

    • Daxx is essential for Mdm2 stability; Daxx downregulation decreases Mdm2 levels, while Daxx overexpression increases them.
    • Daxx binds to both Mdm2 and Hausp, mediating Hausp's stabilizing effect on Mdm2.
    • Daxx enhances Mdm2's intrinsic E3 ligase activity towards p53.
    • Daxx dissociates from Mdm2 upon DNA damage, correlating with Mdm2 self-degradation.

    Conclusions:

    • Daxx modulates Mdm2 function at multiple levels, including stability, interaction with Hausp, and E3 ligase activity.
    • The dissociation of Daxx from Mdm2 during DNA damage is a critical event for p53 activation.
    • Targeting the Mdm2-Daxx interaction represents a potential therapeutic strategy for activating p53 in cancer treatment.